Joachim Albers

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 12

Top Topics

Tyrosine Kinase

Dna Damage Response

Ejection Fraction

Top Venues

Cancer research communications

International journal of molecular sciences

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Michaela Poliaková Turan, Rahel Riedo, Matúš Medo, Chiara Pozzato, Manja Friese-Hamim, Jonas Paul Koch, Si'Ana A Coggins, Qun Li, Baek Kim, Joachim Albers, Daniel Matthias Aebersold, Nicola Zamboni, Yitzhak Zimmer, Michaela Medová
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. Cancer research communications 4 (7) (2024)
Michaela Poliaková Turan, Rahel Riedo, Matúš Medo, Chiara Pozzato, Manja Friese-Hamim, Jonas Paul Koch, Si'Ana A Coggins, Qun Li, Baek Kim, Joachim Albers, Daniel Matthias Aebersold, Nicola Zamboni, Yitzhak Zimmer, Michaela Medová
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. Cancer research communications 4 (7) (2024)
Shukui Qin, Hongming Pan, Jean Frédéric Blanc, Véronique Grando, Ho Yeong Lim, Xin Ying Chang, Aurora O'Brate, Christopher Stroh, Manja Friese-Hamim, Joachim Albers, Andreas Johne, Sandrine Faivre
Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence. JCO precision oncology 8 (2024)
Steffie Revia, Felix Neumann, Julia Jabs, Florian Orio, Christian Sirrenberg, Astrid Zimmermann, Christiane Amendt, Joachim Albers
Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models. International journal of molecular sciences 25 (10) (2024)
Steffie Revia, Felix Neumann, Julia Jabs, Florian Orio, Christian Sirrenberg, Astrid Zimmermann, Christiane Amendt, Joachim Albers
Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models. International journal of molecular sciences 25 (10) (2024)
Michaela Poliaková Turan, Rahel Riedo, Matúš Medo, Chiara Pozzato, Manja Friese-Hamim, Jonas Paul Koch, Si'Ana A Coggins, Qun Li, Baek Kim, Joachim Albers, Daniel Matthias Aebersold, Nicola Zamboni, Yitzhak Zimmer, Michaela Medová
E2F1-associated purine synthesis pathway is a major component of the MET-DNA damage response network. Cancer research communications (2024)
Michaela Poliaková Turan, Rahel Riedo, Matúš Medo, Chiara Pozzato, Manja Friese-Hamim, Jonas Paul Koch, Si'Ana A Coggins, Qun Li, Baek Kim, Joachim Albers, Daniel Matthias Aebersold, Nicola Zamboni, Yitzhak Zimmer, Michaela Medová
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. Cancer research communications 4 (7) (2024)
Steffie Revia, Felix Neumann, Julia Jabs, Florian Orio, Christian Sirrenberg, Astrid Zimmermann, Christiane Amendt, Joachim Albers
Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models. International journal of molecular sciences 25 (10) (2024)
Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh, Andreas Johne, Niki Karachaliou, Andree Blaukat
The preclinical pharmacology of tepotinib - a highly selective MET inhibitor with activity in tumors harboring MET alterations. Molecular cancer therapeutics (2023)
Steffie Revia, Magdalena A Budzinska, Olga Bogatyrova, Felix Neumann, Astrid Zimmermann, Christiane Amendt, Joachim Albers
DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models. Cancers 16 (1) (2023)
Steffie Revia, Magdalena A Budzinska, Olga Bogatyrova, Felix Neumann, Astrid Zimmermann, Christiane Amendt, Joachim Albers
DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models. Cancers 16 (1) (2023)
Adrian Mariño-Enriquez, Jan Philipp Novotny, Doga C Gulhan, Isabella Klooster, Antuan V Tran, Macy Kasbo, Meijun Z Lundberg, Wen-Bin Ou, Derrick L Tao, Daniel F Pilco-Janeta, Victor Y Mao, Frank T Zenke, Brittaney A Leeper, Prafulla C Gokhale, Glenn S Cowley, Laurence H Baker, Karla V Ballman, David E Root, Joachim Albers, Peter J Park, Suzanne George, Jonathan A Fletcher
Hyper-Dependence on NHEJ Enables Synergy Between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)